From early drug discovery to commercial-scale manufacturing, contract development and manufacturing organisations (CDMOs) streamline drug development and manufacturing by offering end-to-end integrated services.
Process consolidation enables CDMOs to achieve efficiency by sharing real-time data, facilitating agile decision making, mitigating logistical hurdles, reducing the time and resources required to transition between development stages and ensuring consistent communication among stakeholders.
Kevin Sharp, Executive Vice President, Head of Sales and Operations at Samsung Biologics, reports.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
